retatrutide phase 3 trial dosing schedule Reta clinical data & — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in trials for metabolic health — targeting GLP-1, GIP Retatrutide Dosing Guide for Researchers

Proven results: Evidence-based weight loss rather than trial-and-error products

The enantiomer of allopregnanolone prevents pressure-mediated retinal degeneration via autophagy

Semaglutide is a newer drug, and it is FDA-approved for weight-loss Semaglutide is a much newer injectable drug that mimics an important hunger-regulating hormone in our bodies, called GLP-1

What the research shows In the SURMOUNT-1 trial, adults taking once-weekly tirzepatide lost an average of about 15% to 21% of their body weight over 72 weeks depending on dose

Cost and insurance coverage are the top reasons consumers say they arent taking a GLP-1 drug

To find out more about the latest research visit our HealthAid Blog